



UNIVERSITY OF LEEDS

This is a repository copy of *AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions*.

White Rose Research Online URL for this paper:

<http://eprints.whiterose.ac.uk/108771/>

Version: Accepted Version

---

**Article:**

Paice, JA, Mulvey, M [orcid.org/0000-0002-6357-3848](https://orcid.org/0000-0002-6357-3848), Bennett, M [orcid.org/0000-0002-8369-8349](https://orcid.org/0000-0002-8369-8349) et al. (6 more authors) (2017) AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions. *Journal of Pain*, 18 (3). pp. 233-246. ISSN 1526-5900

<https://doi.org/10.1016/j.jpain.2016.10.020>

---

© 2016 Published by Elsevier Inc. on behalf of the American Pain Society. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International <http://creativecommons.org/licenses/by-nc-nd/4.0/>

**Reuse**

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.




[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

# Accepted Manuscript

AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions

Judith A. Paice, PhD, RN, Matt Mulvey, PhD, Michael Bennett, MD, Patrick M. Dougherty, PhD, John T. Farrar, MD, PhD, Patrick W. Mantyh, PhD, Christine Miaskowski, RN, PhD, Brian Schmidt, DDS, MD, PhD, Thomas J. Smith, MD



PII: S1526-5900(16)30312-1

DOI: [10.1016/j.jpain.2016.10.020](https://doi.org/10.1016/j.jpain.2016.10.020)

Reference: YJPAI 3323

To appear in: *Journal of Pain*

Received Date: 23 April 2016

Revised Date: 11 October 2016

Accepted Date: 26 October 2016

Please cite this article as: Paice JA, Mulvey M, Bennett M, Dougherty PM, Farrar JT, Mantyh PW, Miaskowski C, Schmidt B, Smith TJ, AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions, *Journal of Pain* (2016), doi: 10.1016/j.jpain.2016.10.020.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions**

Judith A. Paice, PhD, RN  
Division of Hematology-Oncology  
Northwestern University, Feinberg School of Medicine  
Chicago, IL

Matt Mulvey, PhD  
Academic Unit of Palliative Care  
Leeds Institute of Health Sciences  
University of Leeds  
Leeds, UK

Michael Bennett, MD  
Academic Unit of Palliative Care  
Leeds Institute of Health Sciences  
University of Leeds  
Leeds, UK

Patrick M. Dougherty, PhD  
The Division of Anesthesia and Critical Care Medicine  
The University of Texas M.D. Anderson Cancer Center  
Houston, TX

John T. Farrar, MD, PhD  
Department of Epidemiology, Neurology, and Anesthesia  
University of Pennsylvania  
Philadelphia, PA

Patrick W. Mantyh, PhD  
Department of Pharmacology  
University of Arizona  
Tucson, AZ

Christine Miaskowski, RN, PhD  
Department of Physiological Nursing  
University of California  
San Francisco, CA

Brian Schmidt, DDS, MD, PhD  
Bluestone Center for Clinical Research  
New York University College of Dentistry  
New York, NY

Thomas J. Smith, MD  
Department of Oncology  
The Johns Hopkins Hospital

Baltimore, MD

***Corresponding Author:***

Judith A. Paice, PhD, RN

Director, Cancer Pain Program

Division of Hematology-Oncology

676 N. St. Clair Street, Suite 850

Chicago, IL 60611

312-695-4157

312-695-6189 fax

j-paice@northwestern.edu

ACCEPTED MANUSCRIPT

**Disclosures:**

The views expressed in this article are those of the authors, none of whom has financial conflicts of interest relevant to the issues discussed in this manuscript. No official endorsement by the US Food and Drug Administration (FDA) should be inferred. Support was provided by the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTION) public-private partnership with the FDA, which has received contracts, grants, and other revenue for its activities from the FDA, multiple pharmaceutical and device companies, and other sources. A complete list of current ACTION sponsors is available at: <http://www.action.org/partners>.

**Abstract**

Chronic cancer pain is a serious complication of malignancy or its treatment. Currently, no comprehensive, universally accepted cancer pain classification system exists. Clarity in classification of common cancer pain syndromes would improve clinical assessment and management. Moreover, an evidence-based taxonomy would enhance cancer pain research efforts by providing consistent diagnostic criteria, ensuring comparability across clinical trials. As part of a collaborative effort between the Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks (ACTTION) and the American Pain Society (APS), the ACTTION-APS Pain Taxonomy (AAPT) initiative worked to develop the characteristics of an optimal diagnostic system.<sup>59, 65</sup> Following the establishment of these characteristics, a working group consisting of clinicians and clinical and basic scientists with expertise in cancer and cancer-related pain was convened to generate core diagnostic criteria for an illustrative sample of 3 chronic pain syndromes associated with cancer (i.e., bone pain and pancreatic cancer pain as models of pain related to a tumor) or its treatment (i.e., chemotherapy-induced peripheral neuropathy). A systematic review and synthesis was conducted to provide evidence for the dimensions that comprise this cancer pain taxonomy. Future efforts will subject these diagnostic categories and criteria to systematic empirical evaluation of their feasibility, reliability and validity and extension to other cancer-related pain syndromes.

**Perspective**

The ACTTION-APS chronic cancer pain taxonomy provides an evidence-based classification for 3 prevalent syndromes, namely malignant bone pain, pancreatic cancer pain, and chemotherapy-induced peripheral neuropathy. This taxonomy provides consistent diagnostic criteria, common features, co-morbidities, consequences, and putative

mechanisms for these potentially serious cancer pain conditions that can be extended and applied with other cancer-related pain syndromes.

***Key words***

Cancer pain, taxonomy, bone pain, chemotherapy-induced peripheral neuropathy, pancreatic cancer

ACCEPTED MANUSCRIPT

## AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions

### Introduction

One significant barrier to better understanding the growing dilemma of chronic cancer pain is the lack of consistent diagnostic criteria that can be used in research and clinical settings. A common taxonomy would provide a foundation for studies of the prevalence, as well as the consequences of these pain syndromes for people with cancer; present evidence for the significance of this problem; support the need for improvements in management; and increase research efforts.<sup>153</sup> This standardized classification system would enhance research efforts by ensuring greater homogeneity in pain conditions across clinical trials and support the development of animal models to replicate these cancer pain conditions. Ultimately, valid and reliable diagnostic criteria would facilitate clinical assessment and management and potentially guide prognostic accuracy.<sup>59, 65</sup>

Current systems to classify cancer pain provide general clinical utility. Cancer pain is often organized by its intensity (e.g., mild, moderate or severe), its expected time course (e.g., acute versus chronic), its presumed underlying pathophysiology (e.g., nociceptive versus neuropathic), its location (e.g., head and neck pain), or its putative mechanisms (e.g., tumor-related, treatment-related, pain unrelated to tumor or treatment).<sup>126</sup> Although these general categories are useful, more specific diagnostic criteria would allow more precise diagnosis with therapeutic implications and would enhance research efforts.

This lack of a unified taxonomy is not specific to cancer pain. Currently, there is an absence of evidence-based classification systems for most chronic pain conditions.<sup>65</sup> To meet this need, the Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks (ACTTION), a public-private partnership with the U.S. Food and Drug Administration and the American Pain Society (APS) collaborated to



develop the ACTION-APS Pain Taxonomy (AAPT). The initiative worked to develop the characteristics of an ideal diagnostic system that would be biologically plausible, exhaustive, mutually exclusive, reliable, clinically useful, and simple through consensus conferences. The resulting diagnostic system includes 5 dimensions:

1. Core diagnostic criteria
2. Common features
3. Common medical comorbidities
4. Neurobiological, psychological, and functional consequences
5. Putative neurobiological and psychosocial mechanisms, risk factors, and protective factors.<sup>65</sup>

Following the establishment of these 5 dimensions, a working sub-group of clinical and basic scientists and clinicians with expertise in cancer pain was convened by the AAPT organizers. The aim of their effort was to apply the ideal framework of 5 dimensions developed during the original AAPT conference to cancer pain. The objectives included: (1) to identify chronic pain syndromes seen in oncology with high prevalence and significant impact and (2) to generate a classification system of diagnostic criteria for several of these syndromes based on these originally proposed 5 dimensions.

## Methods

A working group of clinicians and clinical and basic scientists with expertise in cancer pain met during a consensus meeting held in July 2014. Group members from the United States and the United Kingdom were carefully selected based upon their contributions to the science and management of cancer pain, representing multiple disciplines (basic scientists, physicians, and nurses) with significant achievements in cancer-related epidemiology, research, and clinical care.

Prior to this meeting, a systematic review was conducted by two of the working group members (MM, MB) using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting system.<sup>99</sup> PRISMA is an evidence-based minimum set of items for reporting systematic reviews and meta-analyses. The databases searched included the following: the Cumulative Index to Nursing and Allied Health Literature (CINAHL) from 1981 to June 2014; the Cochrane Library of Systematic Reviews and the Cochrane Library of Controlled Trials from inception to June 2014; Database of Abstracts of Reviews of Effect from inception to April 2014; Embase Classic and Embase from 1947 to June 2014; Ovid MEDLINE® 1946 to June 2014; and OVID MEDLINE® In-Process and Other Non-Indexed Citations on June 11, 2014. These databases were searched for review articles (including summary reports, systematic reviews, and meta-analyses), as well as observational and experimental studies published in English. Articles were excluded if they did not describe the clinical characteristics of chronic cancer pain, including those that described animal studies, or were studies of acute or breakthrough cancer pain. Data were extracted and summarised descriptively with respect to the 5 AAPT diagnostic dimensions: (1) core diagnostic criteria, (2) common features, (3) common medical co-morbidities, (4) neurobiological, psychosocial and functional consequences, (5) putative neurobiological and psychosocial mechanisms, risk factors, and protective factors. Figure 1 illustrates the process employed in this systematic review. Key words included cancer pain, malignancy, chemotherapy, surgery, radiotherapy and neuropathy.

Bone pain, post-mastectomy pain, head and neck pain, neuropathic pain (disease related), and chemotherapy-induced peripheral neuropathy were most frequently referenced. These results were correlated with prevalence data of pain reported by tumor site, that generally demonstrate higher rates of pain reports in people with pancreatic, lung,

genitourinary, breast and prostate cancers.<sup>20</sup> The expert panel considered these and other pain syndromes aiming to initiate the process of taxonomy development with 3 syndromes before extending to the full range of cancer-related pain syndromes at a later time. The challenge in narrowing the selection to 3 syndromes was to achieve a balance between the most prevalent cancer pain syndromes versus areas that have received the most study and thus have the largest body of evidence. Ultimately guiding the selection was the aim to identify those syndromes with clinical or research utility (i.e., the painful conditions that are most homogeneous in terms of mechanism or presentation and offer the most relevant targets for further research).

Through working group discussion, debate and verbal consensus, 3 chronic pain syndromes seen as a result of cancer (i.e., bone pain and pancreatic cancer pain as a model of pain related to the tumor) or its treatment (chemotherapy-induced peripheral neuropathy) were unanimously selected. Head and neck pain was omitted because the source of this pain may be multifactorial (e.g., tumor, treatment related, or both) and diverse in relationship to specific anatomic location. Similarly, the working group agreed that disease-related neuropathic pain was too broad. While post-surgical pain syndromes, including post-mastectomy pain, were initially included, this group of pain conditions was omitted from the cancer-related pain taxonomy to avoid overlap with a broader discussion of post-surgical pain syndromes being conducted concurrently by a separate working group classifying neuropathic pain.

Then the cancer pain working group generated a classification for these syndromes based upon the AAPT multidimensional framework. This work was conducted during the consensus meeting and later refined through on-line discussion. To ensure that the references were timely, the entire literature review was updated as of January 2015. The

manuscript reporting these findings was written by several members (JAP, MM, MB) and reviewed, edited and approved by all members of the working group.

## Results

Based on this qualitative review and after extensive discussion, the diagnostic criteria for 3 representative chronic cancer-related pain syndromes were developed collectively by the working group, including cancer-induced bone pain (CIBP), chemotherapy induced peripheral neuropathy (CIPN), and pancreatic cancer pain (PCP).

### ***Cancer-Induced Bone Pain***

It is estimated that 50-95% of all patients who die from cancer have bone involvement.<sup>48, 132</sup> The most common cancers to originate in the bone are osteosarcomas.<sup>84</sup> Cancers that frequently metastasize to bone include prostate, breast, lung, and myeloma.<sup>6, 7, 14, 29, 38, 42, 47, 50, 52, 75, 87, 94, 106, 136</sup> Of those with bone metastases, approximately 85% experience pain, with resultant immobility and reduced quality of life.<sup>54</sup> CIBP is a specific pain state with overlapping but distinct features of both acute nociceptive, inflammatory, and neuropathic pain processes.<sup>61</sup>

#### *Dimension 1. Core diagnostic criteria of CIBP*

The AAPT core diagnostic criteria for CIBP are summarized in Table 1. The history must include a cancer diagnosis and imaging evidence of bone disease consistent with primary or metastatic cancer.

#### *Dimension 2. Common features of CIBP*

The cardinal feature of CIBP is a mixture of continuous background pain (usually described as annoying, dull, gnawing, aching, and/or nagging) punctuated by evoked or spontaneous pain (often described as electric or shock-like) in one or more locations generally consistent with the given known distribution of bone lesions, associated with

weight bearing or movement or can occur spontaneously.<sup>14, 22, 40, 43, 49, 61, 63, 72, 73, 85, 88, 92, 95, 113, 123, 125, 130, 132, 133, 140</sup> Generalised bone pain can occur due to the presence of multiple bone lesions or resultant expansion of bone marrow from bone metastases.<sup>27, 61</sup> The distribution of the pain can be localised, radicular, or both.<sup>73</sup>

Typical sites of CIBP include the vertebrae (lower thoracic spine and lumbar regions are most prevalent), pelvis, long bones, and ribs.<sup>27, 49</sup> Bone lesions on the skull can result in headache pain due to calvarial, maxillary, or medullary lesions, as well as cranial nerve palsies such as mental nerve numbness or visual difficulties.<sup>25, 27</sup> Chest wall pain can occur as a result of bone lesions in the ribs.<sup>27</sup>

As the disease and tumor mass progress, the background pain increases in intensity and interference<sup>61</sup> and is generally responsive to opioid analgesics, alone or in conjunction with nonsteroidal anti-inflammatory drugs.<sup>10, 22, 63, 71, 79, 112</sup> Conversely, spontaneous pain (without specific eliciting stimuli) and evoked pain (i.e., in response to standing, weight bearing, movement, touch or other stimuli) associated with CIBP are difficult to treat from the onset due to their intermittent nature, which tends to be very rapid in onset, intense, and of short duration.<sup>10, 22, 63, 71, 79, 112</sup> Terminology commonly used in the clinical setting to describe evoked or spontaneous pain include breakthrough pain, incident pain or a pain flare; however, definitions for these terms often lack precision and may overlap. For example, breakthrough pain is defined as a transitory flare of pain in the setting of chronic pain managed with opioid drugs,<sup>127</sup> yet the evoked pain seen in CIBP can occur during weight bearing without current opioid use. The International Association for the Study of Pain (IASP) Taxonomy, the principal resource for definitions related to chronic pain, does not currently address evoked, breakthrough, incident, flare or spontaneous pain.

### *Dimension 3. Common medical comorbidities for CIBP*

The primary comorbidity for CIBP is the presence of skeletal related events. These skeletal complications include pathological fractures of long bones, vertebrae, pelvis, rib, and other sites<sup>11, 24, 25, 27, 28, 48, 51, 154</sup> and in some cases spinal cord compression.<sup>63, 73, 132, 56</sup>

#### *Dimension 4. Neurobiological, psychosocial, and functional consequences of CIBP*

The consequences of CIBP can be serious because they affect biological, psychological, and functional aspects of the patient's life.<sup>38, 73, 137</sup> Although some pathologic fractures produce limited pain, primary or metastatic bone lesions affecting the femur, pelvis, or spine are likely to cause significant pain during standing or ambulation, resulting in reduced mobility.<sup>63</sup> Reduced quality of life and diminished activities of daily living are associated with CIBP.<sup>41, 44, 48, 49, 91, 118, 132, 134, 160</sup> Functional impairment is strongly associated with evoked or breakthrough pain.<sup>92, 113</sup> Fatigue is frequently reported in patients with metastatic bone disease and resultant pain.<sup>133</sup>

Depression is common in people with painful bone metastases and has been found to be significantly associated with impaired quality of life.<sup>134</sup> Additionally, the meaning of pain as a sign of advancing disease in those individuals with CIBP has been demonstrated to be correlated with increased pain intensity.<sup>134</sup> Anxiety in men with advanced prostate cancer is associated with increase pain intensity and number of metastatic bone lesions.<sup>86</sup> These studies reveal that the consequences of CIBP are not unlike those seen in chronic non-cancer pain syndromes, including impaired function, mood, and quality of life.<sup>60, 155</sup>

#### *Dimension 5. Putative neurobiological and psychosocial mechanisms, risk factors, and protective factors for CIBP*

CIBP is a mixed mechanism condition that includes elements of acute nociceptive pain, inflammatory pain, and neuropathic pain.<sup>58, 61, 70, 103, 125, 132</sup> Distinctive peripheral

modifications to bone and nervous tissues occur as well as neurobiological changes at the level of the spinal cord.<sup>61, 70</sup>

Acute nociceptive pain occurs due to localised bone destruction, which leads to loss of structural integrity and a decrease in pH. Cancer cells do not destroy bone directly, but rather they express the receptor activator of nuclear factor k-B ligand (RANKL), which binds to its receptor, RANK. Activation of the RANKL/RANK pathway stimulates the production of bone destroying osteoclasts.<sup>103</sup> Osteoclasts resorb bone by forming a highly acidic environment between the osteoclast and the bone. This stimulates the TRPV1 or ASIC3 channels expressed by a significant population of nociceptors that ultimately leads to the perception of incident pain with movement and weight bearing activities.<sup>61</sup>

Inflammatory pain develops when peripheral nerve endings in bone marrow and bone matrix are sensitized by localised inflammatory mediators stimulated by the cancer cells or their associated stromal cells. Locally released factors include bradykinin, endothelins, interleukin (IL)-6, granulocyte–macrophage colony-stimulating factor, nerve growth factor (NGF), proteases, and tumor necrosis factor (TNF)- $\alpha$ .<sup>103</sup> This change is generally associated with steady background pain.<sup>61</sup>

Neuropathic pain results from compression, distension, increase in sprouting, or denervation of nerve endings and/or axonal structures caused by expansion of the tumor. These changes lead to spontaneous pain and associated altered sensations.<sup>61</sup>

Nociceptive and neuropathic mechanisms work in concert to produce a complex mixture of ongoing acute, inflammatory and neuropathic processes. These processes lead to a hyper-excitability state within the spinal cord, which itself is associated with amplification and modification of noxious and non-noxious peripheral stimuli.<sup>61, 70, 156</sup>

Interventions to protect against CIBP have been developed based upon current understanding of the underlying neurobiology. Bisphosphonates bind to bone, interfering with osteoclast function, later resulting in osteoclast apoptosis.<sup>103</sup> Osteoprotegerin or denosumab, therapies that interfere with RANKL binding to RANK deplete activated osteoclasts, reduce signs of bone resorption, and diminish bone cancer pain.<sup>146</sup> This is a rapidly evolving area of research and numerous studies are underway to examine compounds that might block CIBP.<sup>146</sup> Regarding putative psychosocial mechanisms associated with CIBP or other risk factors, little is currently understood and additional research is warranted.

### ***Chemotherapy-Induced Peripheral Neuropathy***

Chemotherapy induced peripheral neuropathy (CIPN) is a serious treatment induced toxicity that can limit function, impair quality of life, and in some cases, diminish the potential for cure when chemotherapy doses need to be reduced.<sup>9</sup> This condition is increasing in prevalence as greater numbers of neurotoxic agents are introduced and as patients live longer with the consequences of neuropathy. In a recent systematic review of 31 studies with data from 4179 patients, CIPN prevalence was 68.1% (57.7–78.4) in the first month after chemotherapy, 60.0% (36.4–81.6) at 3 months and 30.0% (6.4–53.5) at 6 months or later.<sup>141</sup>

#### ***Dimension 1. Core diagnostic criteria of CIPN***

CIPN occurs in oncology patients when treatment involves a neurotoxic agent. A temporal relationship exists between the onset of symptoms and the starting, stopping, and duration of therapy.<sup>34, 37, 46, 62, 78, 148</sup> Peripheral sensory and motor nerve damage or dysfunction are the putative mechanisms for CIPN.<sup>36, 37, 62, 101, 121, 148, 151, 162</sup>



CIPN poses a significant challenge for the patient and clinician in terms of diagnosis, management and associated reductions in function and quality of life, particularly in patients with coexisting conditions or disorders that involve the peripheral nervous system (e.g., diabetes, HIV).<sup>2, 33, 68, 78, 80, 81, 104, 120, 121, 148, 151</sup> Table 2 lists the core diagnostic criteria for CIPN.

### *Dimension 2. Common features of CIPN*

The cardinal feature of dose-limiting CIPN is a gradually-progressive distal symmetrical sensory neuropathy (stocking/glove distribution), which may be associated with diminished motor function. However, more often than not motor symptoms are absent until later stages of CIPN.<sup>3, 13, 36, 37, 62, 78, 80, 101, 121, 148, 151, 162</sup> Neuropathy in the feet without involvement in the hands is common. In addition to descriptors such as “tingling” or “burning”, patients often describe these sensory abnormalities with terms such as “discomfort” or “unpleasant”. Cramping, more common in the lower limbs, may be reported.<sup>151</sup>

Clinical examination reveals sensory loss to one or more sensory modalities and/or evoked pain in a stocking and glove distribution. These findings include hypoesthesia (a bilateral increase in detection thresholds to tactile, vibration, or non-noxious warm or cool stimuli)<sup>53, 57, 78</sup>, or hypoalgesia (a bilateral increase in pain detection thresholds to blunt pressure or pinprick stimuli)<sup>53, 57, 78</sup>, or hyperalgesia (a bilateral decrease in pain detection threshold to noxious heat or cold stimuli.)<sup>18, 53</sup> The anatomic distribution of these physical examination findings may not correspond exactly to the sensory symptoms.<sup>2, 30, 46, 53, 78, 80, 109, 115, 120, 148, 152, 158, 162</sup>

Signs and symptoms of CIPN, including pain, commonly begin in the lower extremities followed by the upper extremities and progress proximally.<sup>78</sup> However, not all

go on to experience neuropathy in the upper extremities. The temporal features of CIPN are rapid onset (hours or days) of sensory abnormalities following initiation of neurotoxic chemotherapy.<sup>78, 101</sup> In the majority of cases, the onset of CIPN symptoms and signs is progressive; beginning with mild paraesthesias in the lower extremities, becoming progressively more intense, and advancing proximally with cumulative dose exposure.<sup>78, 101</sup>

Some patients may experience a reduction in the intensity of symptoms between treatment cycles – sometimes referred to as a waxing and waning effect.<sup>122</sup> In some cases, symptoms and signs of CIPN may continue or worsen after treatment has ended, a phenomenon known as ‘coasting’.<sup>37, 78, 101</sup> Increasing evidence suggests that pre-existing sensory deficits (clinical or sub-clinical neuropathy) are associated with the onset of more extensive and severe CIPN symptoms and signs.<sup>18, 53</sup> The prevalence of autonomic changes associated with CIPN is poorly understood, but can include serious complications such as falls related to orthostatic hypotension.<sup>1</sup>

Agents most likely to result in CIPN include platinum based drugs (e.g., cisplatin, carboplatin, and oxaliplatin), vinca alkaloids (e.g., vincristine, vinblastine), taxanes (e.g., paclitaxel, docetaxel), bortezomib, thalidomide, lenalidomide, eribulin, and ixabepilone. The frequency and severity of CIPN is generally related to the specific drug, dose, schedule (e.g., more prevalent with weekly versus every 3 week dosing of paclitaxel), speed of administration, and duration of therapy.<sup>111</sup> In the case of bortezomib, route of delivery affected the prevalence of CIPN. Peripheral neuropathy of any grade was significantly less common with subcutaneous bortezomib administration compared to intravenous delivery.<sup>114</sup>

Sensations described by patients vary with the administered chemotherapeutic agent. In a recent prospective study that compared the experience of patients receiving

docetaxel versus oxaliplatin, tingling was the most common symptom experienced by both groups, yet pain and discomfort associated with cold was uniquely reported by those who received oxaliplatin.<sup>157</sup>

Motor weakness, with a similar peripheral distribution to sensory alterations, can occur in CIPN, but overall is observed less frequently than sensory abnormalities.<sup>62, 101, 141</sup> However, patients frequently demonstrate a decrease in mechano-sensory function, as measured by a timed pegboard test or the time taken to button a shirt.<sup>16, 17, 128</sup> Importantly, impaired proprioception is reported by many patients with CIPN, described as feeling unbalanced, particularly in the absence of visual cues when walking or standing (e.g., in dark settings, when closing one's eyes in the shower).<sup>78, 116</sup> Clinical examination may reveal a positive Romberg sign and generalised ataxia in more severe cases.<sup>124</sup> Symmetrical loss of deep tendon reflexes (Achilles or brachioradialis) is a sign of more advanced CIPN.<sup>78</sup>

### *Dimension 3. Common medical comorbidities of CIPN*

People at greatest risk for CIPN are believed to include those with comorbid conditions known to contribute to neuropathy, including diabetes, obesity, and HIV.<sup>81, 128, 141</sup> Pharmacogenetic profiling of genetic polymorphisms has been conducted to identify susceptibility to CIPN based on genetic polymorphisms. For example, polymorphisms in the *CYP2C8* and *CYP3A5* genes that encode for paclitaxel metabolizing enzymes were found to be associated with CIPN.<sup>31, 82</sup> Even though pharmacogenetic profiling may one day identify patients at greater risk for severe CIPN, the data so far are insufficient to draw any definitive conclusions.

### *Dimension 4. Neurobiological, psychosocial, and functional consequences of CIPN*

Terminal axonal degeneration and axonal microtubule disruption are the most common pathophysiologic consequences observed in CIPN.<sup>78</sup> Psychosocial consequences of

CIPN include depression, anxiety, impaired sleep and other mood changes.<sup>69, 83, 151, 157</sup> The functional outcomes of CIPN range from mild symptoms which do not interfere with activities of daily living (ADL) to moderate and severe dose-limiting sensory and motor alterations that interfere with ADLs.<sup>32, 34-37, 131</sup> The need to limit doses of chemotherapy due to CIPN can lead to shortened survival. In the most severe cases sensory and motor alterations are disabling, resulting in paralysis, complete loss of function, or both.<sup>101, 104, 147</sup>

*Dimension 5. Putative neurobiological and psychosocial mechanisms, risk factors, and protective factors for CIPN*

The underlying pathophysiologic mechanism(s) that lead to the development of CIPN are not completely understood. Nevertheless, the similarity in the pattern and spectrum of clinical symptoms and signs of CIPN caused by different chemotherapeutic agents is apparent. Common underlying mechanisms purported to be involved in the development of CIPN are:<sup>5, 12, 23, 62, 77, 119, 122, 152, 161, 162</sup>

- Disruption of axoplasmic microtubule-mediated transport causing distal axonopathy, a known cellular effect of many chemotherapy agents
- Distal axonal degeneration
- Direct damage to sensory nerve cell bodies of the dorsal root ganglia
- Mitochondrial dysfunction
- Activation of protein kinases and extracellular kinases (associated with cisplatin-induced CIPN)
- Oxaliplatin is associated with actual nerve cell death and decreased epidermal nerve fiber density with each cycle, as well as decreased conduction velocity and amplitude
- Alteration of gene expression thought to be involved in pain mediation in spinal cord dorsal horn (associated with vincristine exposure)

- Decrease in the density of grey matter after one month in women with breast cancer experiencing CIPN
- Central sensitization as a consequence of long-term peripheral nerve injury

A recent systematic review explored risk factors for CIPN and found the following elements: baseline neuropathy, smoking, abnormal creatinine clearance and distinct sensory changes during chemotherapy treatment, including cold allodynia and cold hyperalgesia.<sup>141</sup> Sensory changes during chemotherapy treatment, including increased pain and neuronal hyperexcitability, are also predictors of CIPN.<sup>141</sup> A prospective study of patients receiving oxaliplatin and followed for 1 year found that those patients with elevated heat detection thresholds (higher temperature levels were needed to perceive heat) before receiving chemotherapy were more likely to experience intense CIPN.<sup>128</sup>

Few protective factors for CIPN have been identified. A recent investigation employed large Medicare claims data and found that a history of autoimmune disease was associated with reduced risk of CIPN.<sup>81</sup> Regarding prevention of CIPN, a recent clinical practice guideline from the American Society of Clinical Oncology reviewed existing evidence. After extensive analysis, the authors were unable to recommend any agents to prevent this syndrome due to the lack of high quality evidence.<sup>80</sup>

### ***Pancreatic cancer pain***

The estimated incidence of pancreatic cancer for 2016 is more than 53,000 in the U.S., with approximately 42,000 dying from this disease.<sup>144</sup> Risk factors for pancreatic cancer include family history, obesity, smoking, and chronic pancreatitis.<sup>89, 145, 149</sup> Upper abdominal pain is a common presenting symptom of pancreatic cancer. The prevalence of pain associated with pancreatic cancer ranges from 72-100%.<sup>15</sup>

### ***Dimension 1. Core diagnostic criteria of PCP***

Pancreatic cancer pain occurs in the presence of a diagnosis of pancreatic cancer confirmed by imaging evidence of an epigastric mass and/or biopsy that establishes the diagnosis. Table 3 presents the core diagnostic criteria.

#### *Dimension 2. Common features of PCP*

The cardinal features of pancreatic cancer pain are upper abdominal pain with frequent extension to the back, either to the low back or the region between the scapulae spreading laterally, and unexplained weight loss.<sup>143</sup> Less frequently PCP is diffuse within the abdomen or referred to the lower abdominal quadrants.<sup>26, 90</sup> The pain is often described as dull, aching, gnawing or spasmodic<sup>26, 143</sup> and the intensity can fluctuate throughout the day with position (e.g., exacerbated by supine positioning) and food ingestion.<sup>143</sup> Pain intensity usually increases with disease severity. However, because this cancer is often diagnosed late, 20-30% of patients report moderate to severe pain at diagnosis.<sup>26</sup> The back pain associated with PCP may be worse when the patient is supine and eased by sitting forward.<sup>26, 90, 143</sup>

#### *Dimension 3. Common medical comorbidities of PCP*

Jaundice and dark urine can be a presenting symptom in cancers of the pancreatic head.<sup>143</sup> Unexplained weight loss, anorexia, diabetes, and other sequelae of pancreatic cancer or its treatment are common.<sup>15, 90, 143</sup> To date, few medical comorbidities of pancreatic cancer pain have been identified.

#### *Dimension 4. Neurobiological, psychosocial, and functional consequences of PCP*

Because pancreatic cancer is highly associated with pain, it is difficult to discern whether other symptoms are related to the cancer or pain. Several studies have documented a very high prevalence of depressed mood in those patients with pancreatic

cancer, higher than other cancers with similar prognoses.<sup>8, 26, 45</sup> Symptom burden in general is high in this population, notably including disturbed sleep and fatigue<sup>90</sup> as well as nausea and vomiting associated with obstruction or delayed gastric emptying.<sup>15</sup>

*Dimension 5. Putative neurobiological and psychosocial mechanisms, risk factors, and protective factors for PCP*

Pain occurs in 90% of patients with cancer of the head of the pancreas and is much less common in cancer of pancreatic body or tail.<sup>26, 64, 143</sup> Back pain often indicates that retroperitoneal or celiac plexus infiltration has occurred.<sup>143</sup> Putative mechanisms include compression or infiltration (perineural invasion) of splanchnic nerves in the celiac plexus by direct local tumour expansion,<sup>8, 19, 117, 143</sup> as well as compression of surrounding tissues and organs. Celiac plexus block has been found to be effective in relieving PCP.<sup>4, 107, 135</sup> It is unclear if relief signifies extension of tumor into the plexus, or interruption of visceral afferent neurons that are also found in the plexus. No other risk factors or protective factors for PCP could be identified.

## **Discussion**

Cancer-related pain remains a complex, multidimensional phenomenon. The exercise of developing a standardized, rigorous, valid taxonomy for just 3 common cancer pain syndromes revealed the limitations in our existing nomenclature. Current studies attempting to characterize and establish prevalence rates for specific cancer pain syndromes are hampered by the absence of explicit definitions. A clear example is the large, prospective study by Venzel and colleagues comparing neuropathy characteristics in patients receiving oxaliplatin versus docetaxel.<sup>157</sup> Although the prevalence of pain in the hands and feet was approximately equal between the 2 groups, on further analysis, a significant percentage of those treated with docetaxel reported less burning and numbness,

suggesting the pain was not consistent with CIPN. The investigators postulated this difference may be related to the use of adjuvant endocrine therapies, such as the aromatase inhibitors, often prescribed for those who have received docetaxel. These endocrine therapies are known to cause arthralgias, myalgias and carpal tunnel syndrome.<sup>110, 142</sup> The investigators used a variety of questionnaires to determine these differences, yet not all clinicians or researchers will be able to employ such an extensive battery of measures. It is our hope that the core diagnostic criteria will help future investigators to not only better characterize cancer pain syndromes, as was done in this study, but to differentiate them from related phenomenon to avoid inaccurate interpretations.<sup>100</sup>

The consequences of cancer pain can be significant, including deleterious effects on function, mood, sleep, fatigue, and ultimately, quality of life.<sup>60, 155</sup> Additionally, increased intensity of cancer pain is associated with heightened suffering in those at end of life.<sup>159</sup> Finally, studies support the association between pain and reduced survival, demanding more urgent attention to this symptom.<sup>76, 129</sup> More research is warranted to discern the neurobiological, psychological, and functional consequences of each of these and other cancer pain syndromes.

Another area that demands additional study is the determination of the mechanisms of cancer pain. While important work has begun in the area of CIBP,<sup>39, 102, 103, 105</sup> CIPN,<sup>66, 74, 97, 98</sup> and PCP,<sup>55, 93</sup> additional research is needed to elucidate the neurobiological factors responsible for cancer pain. An exciting line of investigation is the interactions among the cancer microenvironment, the primary afferent nociceptor, and the immune system.<sup>138, 139</sup>



An additional area of clarification relates to risk factors and protective determinants for cancer pain. Early research exploring cancer pain focused on clinical or biological factors, such as cancer diagnosis, stage of disease, or treatment. In recent important work, Miaskowski and colleagues found that cancer patients with the highest symptom burden were significantly younger, more likely to be female and non-white, had lower levels of social support, lower socioeconomic status, poorer functional status, and a higher level of comorbidity.<sup>108</sup> In a large study of people with breast cancer, colorectal cancer or prostate cancer, Lewis et al. found that factors associated with more severe CIPN included colon versus other cancers, the duration and type of therapy, poor socioeconomic status and black race.<sup>96</sup> Factors influencing cancer pain must be expanded in future studies, including psychosocial factors<sup>60</sup> and overlapping chronic pain conditions and comorbidities.<sup>100</sup> Additionally, identification of genetic polymorphisms might allow for the identification of those at risk for these painful syndromes, as well as direct prevention and treatment innovations.

Finally, an emerging area of research that requires further investigation is the development of phenotypic profiles of cancer pain syndromes based on symptoms and clinical signs. Recent studies in non-cancer chronic pain syndromes (such as diabetic peripheral neuropathy) suggest that stratification of patients into homogeneous groups based on symptom profiles may be advantageous for analgesic drug trials and ultimately lead to a more targeted approach to cancer pain management.<sup>67, 150</sup>

This proposed taxonomy presents early work in developing a classification system for cancer related pain conditions. Current classification systems focusing on duration (acute versus chronic) or presumed etiology (related to the cancer, related to treatment, or

unrelated) do not provide the specificity needed to clearly define distinct cancer pain syndromes. There were numerous challenges in the development process, notably limitations in existing research related to cancer pain. Studies are often hampered by a wide array of weaknesses, including heterogeneous populations, small sample sizes, dissimilar assessment tools and techniques, and inadequate duration of investigations. Although the working group strove to identify diagnostic criteria that were absolutely necessary to describe each painful syndrome, once these criteria are applied more broadly, controversy will arise and modification will likely be indicated. Future work will now be required to validate this proposed taxonomy in populations of people with cancer and determine the feasibility of its use in both clinical and research settings. Investigators studying these 3 syndromes should incorporate the core diagnostic criteria when employing research methods. Clinicians may find the use of the criteria of benefit when considering the differential diagnosis of complex cancer pain syndromes. This current undertaking classified just 3 syndromes; much additional work is needed to characterize the many other painful syndromes that occur in those individuals diagnosed with cancer.

## **Conclusions**

Three cancer pain syndromes, 2 related to cancer, and one related to a common cancer treatment, were classified using the AAPT multidimensional chronic pain taxonomy. Future work will demonstrate the validity and reliability of these proposed diagnostic criteria.<sup>21</sup> As our understanding of these cancer pain conditions matures, it is expected that the taxonomy will expand and evolve. It is the hope of this working group that classification of these cancer pain syndromes will ultimately strengthen clinical, scientific and educational efforts around cancer pain. Transforming our understanding of cancer pain is urgently

needed to improve its management as well as improve patients' relief and survivors' quality of life.

ACCEPTED MANUSCRIPT

## References

1. Adams SC, Schondorf R, Benoit J, Kilgour RD. Impact of cancer and chemotherapy on autonomic nervous system function and cardiovascular reactivity in young adults with cancer: a case-controlled feasibility study. *BMC Cancer* 15:414, 2015
2. Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G, Group CI-P. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. *Ann Oncol* 25:257-264, 2014
3. Andersen KG, Jensen MB, Kehlet H, Gartner R, Eckhoff L, Kroman N. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide. *Acta Oncol* 51:1036-1044, 2012
4. Arcidiacono Paolo G, Calori G, Carrara S, McNicol Ewan D, Testoni Pier A: Celiac plexus block for pancreatic cancer pain in adults. *Cochrane Database of Systematic Reviews*. 2011
5. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. *Crit Rev Oncol Hemat* 82:51-77, 2012
6. Bae HM, Lee SH, Kim TM, Kim DW, Yang SC, Wu HG, Kim YW, Heo DS. Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. *Lung cancer* 77:572-577, 2012
7. Bagi CM. Skeletal implications of prostate cancer. *J Musculoskelet Neuronal Interact* 3:112-117, 2003
8. Bapat AA, Hostetter G, Von Hoff DD, Han H. Perineural invasion and associated pain in pancreatic cancer. *Nat Rev Cancer* 11:695-707, 2011
9. Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, Tkaczuk K, Edelman M, Bao T. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. *Springerplus*. 3:366, 2014
10. Bianchi R, Gilardini A, Rodriguez-Menendez V, Oggioni N, Canta A, Colombo T, De Michele G, Martone S, Sfacteria A, Piedemonte G, Grasso G, Beccaglia P, Ghezzi P, D'Incalci M, Lauria G, Cavaletti G. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. *Eur J Cancer* 43:710-717, 2007
11. Bickels J, Dadia S, Lidar Z. Surgical management of metastatic bone disease. *J Bone Joint Surg* 91:1503-1516, 2009
12. Bilinska M, Usnarska-Zubkiewicz L, Pokryszko-Dragan A. Bortezomib-induced painful neuropathy in patients with multiple myeloma. *Wspolczesna Onkologia* 17:421-426, 2013
13. Binda D, Cavaletti G. Chemotherapy induced peripheral neuropathy outcome measures standardisation (CI-PERINOMS) study. *J Peripher Nerv Syst* 16:S12, 2011
14. Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA. Living with advanced but stable multiple myeloma: A study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. *J Pain Symptom Manage* 46:671-680, 2013
15. Bond-Smith G, Banga N, Hammond TM, Imber CJ. Pancreatic adenocarcinoma. *BMJ* 344:e2476, 2012
16. Boyette-Davis JA, Cata JP, Driver LC, Novy DM, Bruel BM, Mooring DL, Wendelschafer-Crabb G, Kennedy WR, Dougherty PM. Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. *Cancer Chemother Pharmacol* 71:619-626, 2013

17. Boyette-Davis JA, Cata JP, Zhang H, Driver LC, Wendelschafer-Crabb G, Kennedy WR, Dougherty PM. Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. *J Pain* 12:1017-1024, 2011
18. Boyette-Davis JA, Eng C, Wang XS, Cleeland CS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Zhang H, Dougherty PM. Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. *Clin Cancer Res* 18:3180-3187, 2012
19. Brant JM. Cancer-related neuropathic pain. *Nurse Pract Forum* 9:154-162, 1998
20. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, Cohen R, Dow L. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. *Ann Oncol* 20:1420-1433, 2009
21. Bruehl S, Ohrbach R, Sharma S, Widerstrom-Noga E, Dworkin RH, Fillingim RB, Turk DC. Approaches to Demonstrating the Reliability and Validity of Core Diagnostic Criteria for Chronic Pain. *J Pain* 17:T118-131, 2016
22. Buga S, Sarria JE. The management of pain in metastatic bone disease. *Cancer Control* 19:154-166, 2012
23. Burakgazi AZ, Messersmith W, Vaidya D, Hauer P, Hoke A, Polydefkis M. Longitudinal assessment of oxaliplatin-induced neuropathy. *Neurology* 77:980-986, 2011
24. Callstrom MR, Charboneau JW, Goetz MP, Rubin J, Atwell TD, Farrell MA, Welch TJ, Maus TP. Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem. *Skeletal Radiol* 35:1-15, 2006
25. Caraceni A. Evaluation and assessment of cancer pain and cancer pain treatment. *Acta Anaesthesiol Scand* 45:1067-1075, 2001
26. Caraceni A, Portenoy RK. Pain management in patients with pancreatic carcinoma. *Cancer* 78:639-653, 1996
27. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. *Pain* 82:263-274, 1999
28. Caraceni A, Weinstein SM. Classification of cancer pain syndromes. *Oncology (Williston Park, N.Y.)* 15:1627-1640, 1642, 2001
29. Carla R, Fabio T, Gloria B, Ernesto M. Prevention and treatment of bone metastases in breast cancer. *J Clin Med* 2:151-175, 2013
30. Cata JP, Weng H, Burton AW, Villareal H, Giral S, Dougherty PM. Quantitative sensory findings in patients with bortezomib-induced pain. *J Pain* 8:296-306, 2007
31. Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. *Lancet Oncol* 12:1151-1161, 2011
32. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Parma G, Lissoni A, Fei F, Cundari S, Zanna C. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. *Neurology* 61:1297-1300, 2003
33. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. *Ann Oncol* 24:454-462, 2013
34. Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. *Eur J Cancer* 46:479-494, 2010
35. Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, Zara G, Plasmati R, Pastorelli F, Caraceni A, Pace A, Manicone M, Lissoni A, Colombo N, Bianchi G, Zanna C. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. *J Peripher Nerv Syst* 12:210-215, 2007

36. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. *Leuk Lymphoma* 51:1178-1187, 2010
37. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. *Nat Rev Neurol* 6:657-666, 2010
38. Cetin K, Christiansen CF, Jacobsen JB, Norgaard M, Sorensen HT. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: A Danish population-based cohort study. *Lung cancer* 247-254, 2014
39. Chartier SR, Thompson ML, Longo G, Fealk MN, Majuta LA, Mantyh PW. Exuberant sprouting of sensory and sympathetic nerve fibers in nonhealed bone fractures and the generation and maintenance of chronic skeletal pain. *Pain* 155:2323-2336, 2014
40. Chen E, Khan L, Zhang L, Nguyen J, Cramarossa G, Tsao M, Danjoux C, Barnes E, Sahgal A, Holden L, Jon F, Dennis K, Culleton S, Chow E. Symptom clusters in patients with bone metastases - A reanalysis comparing different statistical methods. *Support Care Cancer* 20:2811-2820, 2012
41. Cheng EY. Prospective quality of life research in bony metastatic disease. *Clin Orthop Relat Res* 415S:S289-297, 2003
42. Chow E, Doyle M, Li K, Bradley N, Harris K, Hruby G, Sinclair E, Barnes EA, Danjoux C. Mild, moderate, or severe pain categorized by patients with cancer with bone metastases. *J Palliat Med* 9:850-854, 2006
43. Chow E, Fan G, Hadi S, Filipczak L. Symptom clusters in cancer patients with bone metastases. *Support Care Cancer* 15:1035-1043, 2007
44. Chow E, Hruby G, Davis L, Holden L, Schueller T, Wong R, Hayter C, Szumacher E, Loblaw A, Danjoux C. Quality of life after local external beam radiation therapy for symptomatic bone metastases: a prospective evaluation. *Support Cancer Ther* 1:179-184, 2004
45. Clark KL, Loscalzo M, Trask PC, Zabora J, Philip EJ. Psychological distress in patients with pancreatic cancer--an understudied group. *Psychooncology* 19:1313-1320, 2010
46. Cleeland CS, Farrar JT, Hausheer FH. Assessment of cancer-related neuropathy and neuropathic pain. *Oncologist* 15 Suppl 2:13-18, 2010
47. Clemons M, Dranitsaris G, Cole D, Gainford MC. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. *Oncologist* 11:227-233, 2006
48. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. *Cancer Treat Rev* 27:165-176, 2001
49. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res* 12:6243s-6249s, 2006
50. Conti G, La Torre G, Cicalese V, Micheletti G, Ludovico MG, Vestita GD, Cottonaro G, Introini C, Cecchi M. Prostate cancer metastases to bone: observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the METAURO protocol and of patient baseline features. *Arch Ital Urol Androl* 80:59-64, 2008
51. Cook RJ, Major P. Methodology for treatment evaluation in patients with cancer metastatic to bone. *J Natl Cancer Inst* 93:534-538, 2001
52. Coombes RC, Dady P, Parsons C. Assessment of response of bone metastases to systemic treatment in patients with breast cancer. *Cancer* 52:610-614, 1983
53. de Carvalho Barbosa M, Kosturakis AK, Eng C, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Wang XS, Cleeland CS, Dougherty PM. A Quantitative Sensory Analysis of Peripheral Neuropathy in Colorectal Cancer and Its Exacerbation by Oxaliplatin Chemotherapy. *Cancer Res* 5955-5962, 2014
54. Delaney A, Fleetwood-Walker SM, Colvin LA, Fallon M. Translational medicine: cancer pain mechanisms and management. *British J Anesth* 101:87-94, 2008
55. Demir IE, Friess H, Ceyhan GO. Neural plasticity in pancreatitis and pancreatic cancer. *Nat Rev Gastroenterol Hepatol* 12:649-659, 2015

56. Donovan PJ, Achong N, Griffin K, Galligan J, Pretorius CJ, McLeod DS. PTHrP-mediated hypercalcemia: causes and survival in 138 patients. *J Clin Endocrinol Metab* 100:2024-2029, 2015
57. Dougherty PM, Cata JP, Burton AW, Vu K, Weng HR. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. *J Pain Symptom Manage* 33:166-179, 2007
58. Dubey A, Koul R. Bone metastasis -- an overview. *Internet Journal of Pain, Symptom Control & Palliative Care*. 8:6p, 2010
59. Dworkin RH, Bruehl S, Fillingim RB, Loeser JD, Terman GW, Turk DC. Multidimensional Diagnostic Criteria for Chronic Pain: Introduction to the ACTION-American Pain Society Pain Taxonomy (AAPT). *J Pain* 17:T1-9, 2016
60. Edwards RR, Dworkin RH, Sullivan MD, Turk DC, Wasan AD. The Role of Psychosocial Processes in the Development and Maintenance of Chronic Pain. *J Pain* 17:T70-92, 2016
61. Falk S, Dickenson AH. Pain and nociception: mechanisms of cancer-induced bone pain. *J Clin Oncol* 32:1647-1654, 2014
62. Farquhar-Smith P. Chemotherapy-induced neuropathic pain. *Curr Opin Support Palliat Care* 5:1-7, 2011
63. Farrell C. Bone metastases: assessment, management and treatment options. *Br J Nurs* 22:S4, S6, S8-11, 2013
64. Fasanella KE, Davis B, Lyons J, Chen Z, Lee KK, Slivka A, Whitcomb DC. Pain in Chronic Pancreatitis and Pancreatic Cancer. *Gastroenterol Clin North Am* 36:335-364, 2007
65. Fillingim RB, Bruehl S, Dworkin RH, Dworkin SF, Loeser JD, Turk DC, Widerstrom-Noga E, Arnold L, Bennett R, Edwards RR, Freeman R, Gewandter J, Hertz S, Hochberg M, Krane E, Mantyh PW, Markman J, Neogi T, Ohrbach R, Paice JA, Porreca F, Rappaport BA, Smith SM, Smith TJ, Sullivan MD, Verne GN, Wasan AD, Wesselmann U. The ACTION-American Pain Society Pain Taxonomy (AAPT): an evidence-based and multidimensional approach to classifying chronic pain conditions. *J Pain* 15:241-249, 2014
66. Flatters SJ. The contribution of mitochondria to sensory processing and pain. *Prog Mol Biol Transl Sci* 131:119-146, 2015
67. Freeman R, Baron R, Bouhassira D, Cabrera J, Emir B. Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. *Pain* 155:367-376, 2014
68. Geber C, Breimhorst M, Burbach B, Egenolf C, Baier B, Fechir M, Koerber J, Treede RD, Vogt T, Bircklein F. Pain in chemotherapy-induced neuropathy--more than neuropathic? *Pain* 154:2877-2887, 2013
69. Golan-Vered Y, Pud D. Chemotherapy-induced neuropathic pain and its relation to cluster symptoms in breast cancer patients treated with paclitaxel. *Pain Pract* 13:46-52, 2013
70. Gordon-Williams RM, Dickenson AH. Central neuronal mechanisms in cancer-induced bone pain. *Curr Opin Support Palliat Care* 1:6-10, 2007
71. Gough N, Miah AB, Linch M. Nonsurgical oncological management of cancer pain. *Curr Opin Support Palliat Care* 8:102-111, 2014
72. Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. *J Pain Symptom Manage* 33:462-472, 2007
73. Grant R, Papadopoulos SM, Greenberg HS. Metastatic epidural spinal cord compression. *Neurol Clinics* 9:825-841, 1991
74. Griffiths LA, Flatters SJ. Pharmacological Modulation of the Mitochondrial Electron Transport Chain in Paclitaxel-Induced Painful Peripheral Neuropathy. *J Pain* 16:981-994, 2015
75. Hage WD, Aboulafia AJ, Aboulafia DM. Incidence, location, and diagnostic evaluation of metastatic bone disease. *Orthop Clin North Am* 31:515-528, vii, 2000

76. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. *J Clin Oncol* 26:2544-2549, 2008
77. Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). *Front Pharmacol* 4:156, 2013
78. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. *Semin Oncol* 33:15-49, 2006
79. Herdon CM. Pharmacologic management of cancer pain. *J Neurosci Nurs* 35:321-326, 2003
80. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical O. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 32:1941-1967, 2014
81. Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, Minasian LM, Unger J. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. *J Clin Oncol* 34:3014-3022, 2016
82. Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC. CYP2C8\*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. *Ann Oncol* 24:1472-1478, 2013
83. Hong JS, Tian J, Wu LH. The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients. *Curr Oncol* 21:174-180, 2014
84. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. *J Clin Oncol* 33:3029-3035, 2015
85. Janjan NA, Payne R, Gillis T, Podoloff D, Libshitz HI, Lenzi R, Theriault R, Martin C, Yasko A. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. *J Pain Symptom Manage* 16:171-178, 1998
86. Johanes C, Monoarfa RA, Ismail RI, Umbas R. Anxiety level of early- and late-stage prostate cancer patients. *Prostate Int* 1:177-182, 2013
87. Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Bone metastasis as the first manifestation of lung cancer. *Int J Clin Pract* 57:184-186, 2003
88. Kirou-Mauro AM, Hird A, Wong J, Sinclair E, Barnes EA, Tsao M, Danjoux C, Chow E. Has pain management in cancer patients with bone metastases improved? A seven-year review at an outpatient palliative radiotherapy clinic. *J Pain Symptom Manage* 37:77-84, 2009
89. Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, Griffin C, Cameron JL, Yeo CJ, Kern S, Hruban RH. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. *Cancer Res* 64:2634-2638, 2004
90. Krech RL, Walsh D. Symptoms of pancreatic cancer. *J Pain Symptom Manage* 6:360-367, 1991
91. Kurosaka S, Satoh T, Chow E, Asano Y, Tabata K, Kimura M, Tsumura H, Matsumoto K, Ishiyama H, Inoue Y, Hayakawa K, Baba S. EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy. *Ann Nucl Med* 26:485-491, 2012
92. Laird BJ, Walley J, Murray GD, Clausen E, Colvin LA, Fallon MT. Characterization of cancer-induced bone pain: an exploratory study. *Support Care Cancer* 19:1393-1401, 2011
93. Lam DK, Dang D, Flynn AN, Hardt M, Schmidt BL. TMRSS2, a novel membrane-anchored mediator in cancer pain. *Pain* 156:923-930, 2015
94. Lam MGEH, De Klerk JMH, Van Rijk PP. 186Re-HEDP for metastatic bone pain in breast cancer patients. *Eur J Nucl Med Mol Imaging* 31:S162-S170, 2004



95. Langford DJ, Tripathy D, Paul SM, West C, Dodd MJ, Schumacher K, Miaskowski C. Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain. *J Pain* 12:495-507, 2011
96. Lewis MA, Zhao F, Jones D, Loprinzi CL, Brell J, Weiss M, Fisch MJ. Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study. *J Pain Symptom Manage* 49:1016-1024, 2015
97. Li Y, Adamek P, Zhang H, Tatsui CE, Rhines LD, Mrozkova P, Li Q, Kosturakis AK, Cassidy RM, Harrison DS, Cata JP, Sapire K, Zhang H, Kennamer-Chapman RM, Jawad AB, Ghetti A, Yan J, Palecek J, Dougherty PM. The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4. *J Neurosci* 35:13487-13500, 2015
98. Li Y, Zhang H, Kosturakis AK, Cassidy RM, Zhang H, Kennamer-Chapman RM, Jawad AB, Colomand CM, Harrison DS, Dougherty PM. MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy. *Brain Behav Immun* 49:255-266, 2015
99. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med* 151:W65-94, 2009
100. Maixner W, Fillingim RB, Williams DA, Smith SB, Slade GD. Overlapping Chronic Pain Conditions: Implications for Diagnosis and Classification. *J Pain* 17:T93-T107, 2016
101. Malik B, Stillman M. Chemotherapy-induced peripheral neuropathy. *Curr Neurol Neurosci Rep* 8:56-65, 2008
102. Mantyh P. Bone cancer pain: causes, consequences, and therapeutic opportunities. *Pain* 154 Suppl 1:S54-62, 2013
103. Mantyh PW. Bone cancer pain: from mechanism to therapy. *Curr Opin Support Palliat Care* 8:83-90, 2014
104. Massey RL, Kim HK, Abdi S. Brief review: Chemotherapy-induced painful peripheral neuropathy (CIPPN): Current status and future directions. *Can J Anesth* 61:754-762, 2014
105. McCaffrey G, Thompson ML, Majuta L, Fealk MN, Chartier S, Longo G, Mantyh PW. NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use. *Cancer Res* 74:7014-7023, 2014
106. Mendoza TR, Koyyalagunta D, Burton AW, Thomas SK, Phan MH, Giralt SA, Shah JJ, Cleeland CS. Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty. *J Pain* 13:564-570, 2012
107. Mercadante S, Catala E, Arcuri E, Casuccio A. Celiac plexus block for pancreatic cancer pain: factors influencing pain, symptoms and quality of life. *J Pain Symptom Manage* 26:1140-1147, 2003
108. Miaskowski C, Cooper BA, Melisko M, Chen LM, Mastick J, West C, Paul SM, Dunn LB, Schmidt BL, Hammer M, Cartwright F, Wright F, Langford DJ, Lee K, Aouizerat BE. Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. *Cancer* 120:2371-2378, 2014
109. Mick G, Baron R, Correa-Illanes G, Hans G, Mayoral V, Frias X, Sintés D, Keller T. Is an easy and reliable diagnosis of localized neuropathic pain (LNP) possible in general practice? Development of a screening tool based on IASP criteria. *Curr Med Res Opin* 30:1357-1366, 2014
110. Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ, Committee IESS. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. *Lancet Oncol* 13:420-432, 2012

111. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. *Cancer Treat Rev* 40:872-882, 2014
112. Mitera G, Zeiadin N, Kirou-Mauro A, DeAngelis C, Wong J, Sanjeevan T, Sinclair E, Danjoux C, Barnes E, Tsao M, Sahgal A, Chow E. Retrospective assessment of cancer pain management in an outpatient palliative radiotherapy clinic using the Pain Management Index. *J Pain Symptom Manage* 39:259-267, 2010
113. Montgomery K, Laird B, Lesley C, Fallon M. A characterization study of breakthrough pain in cancer induced bone pain. *Palliat Medicine* 26 (4):565-566, 2012
114. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. *Lancet Oncol* 12:431-440, 2011
115. Mulvey MR, Rolke R, Klepstad P, Caraceni A, Fallon M, Colvin L, Laird B, Bennett MI, SIG ICP, the ERN. Confirming neuropathic pain in cancer patients: applying the NeuPSIG grading system in clinical practice and clinical research. *Pain* 155:859-863, 2014
116. Nahman-Averbuch H, Yarnitsky D, Granovsky Y, Sprecher E, Steiner M, Tzuk-Shina T, Pud D. Pronociceptive pain modulation in patients with painful chemotherapy-induced polyneuropathy. *J Pain Symptom Manage* 42:229-238, 2011
117. Niu L, Wang Y, Yao F, Wei C, Chen Y, Zhang L, Chen J, Li J, Zuo J, Xu K. Alleviating visceral cancer pain in patients with pancreatic cancer using cryoablation and celiac plexus block. *Cryobiology* 66:105-111, 2013
118. Nomiya T, Teruyama K, Wada H, Nemoto K. Time course of pain relief in patients treated with radiotherapy for cancer pain: a prospective study. *Clin J Pain* 26:38-42, 2010
119. Nudelman KN, McDonald BC, Wang Y, Smith DJ, West JD, O'Neill DP, Zanville NR, Champion VL, Schneider BP, Saykin AJ. Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy. *J Clin Oncol* 34:677-683, 2016
120. Pachman DR, Watson JC, Lustberg MB, Wagner-Johnston ND, Chan A, Broadfield L, Cheung YT, Steer C, Storey DJ, Chandwani KD, Paice J, Jean-Pierre P, Oh J, Kamath J, Fallon M, Strik H, Koeppen S, Loprinzi CL. Management options for established chemotherapy-induced peripheral neuropathy. *Support Care Cancer* 22:2281-2295, 2014
121. Paice JA. Chronic treatment-related pain in cancer survivors. *Pain* 152:S84-89, 2011
122. Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. *Ca Cancer J Clin* 63:419-437, 2013
123. Phillips LL. Managing the pain of bone metastases in the home environment. *Am J Hosp Palliat Med* 15:32-42, 1998
124. Pignataro RM, Swisher AK. Chemotherapy induced peripheral neuropathy: risk factors, pathophysiology, assessment, and potential physical therapy interventions. *Rehabil Oncol* 28:10-18, 2010
125. Pollen JJ, Schmidt JD. Bone pain in metastatic cancer of prostate. *Urology* 13:129-134, 1979
126. Portenoy RK. Treatment of cancer pain. *Lancet*. 377:2236-2247, 2011
127. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. *Pain* 41:273-281, 1990
128. Reddy SM, Vergo MT, Paice JA, Kwon N, Helenowski IB, Benson AB, Mulcahy MF, Nimeiri HS, Harden RN. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies. *Clin Colorectal Cancer* 15:37-46, 2016
129. Reyes-Gibby CC, Anderson KO, Merriman KW, Todd KH, Shete SS, Hanna EY. Survival patterns in squamous cell carcinoma of the head and neck: pain as an independent prognostic factor for survival. *J Pain* 15:1015-1022, 2014

130. Riccio AI, Wodajo FM, Malawer M. Metastatic carcinoma of the long bones. *Am Fam Physician* 76:1489-1494, 2007
131. Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K. Complications of multiple myeloma therapy, part 1: Risk reduction and management of peripheral neuropathy and asthenia. *J Natl Compr Canc Netw* 8:S4-S12, 2010
132. Rizzoli R, Body JJ, Brandi ML, Cannata-Andia J, Chappard D, El Maghraoui A, Gluer CC, Kendler D, Napoli N, Papaioannou A, Pierroz DD, Rahme M, Van Poznak CH, De Villiers TJ, El Hajj Fuleihan G. Cancer-associated bone disease. *Osteoporos Int* 24:2929-2953, 2013
133. Rodionov V, Bogomolova O, Rodionova M. Clinical symptoms of bone marrow metastases in breast cancer patients. *Breast* 20:S41, 2011
134. Rustoen T, Moum T, Padilla G, Paul S, Miaskowski C. Predictors of quality of life in oncology outpatients with pain from bone metastasis. *J Pain Symptom Manage* 30:234-242, 2005
135. Rykowski JJ, Hilgier M: Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer: influence on pain relief. *Anesthesiology* 92:347-354, 2000
136. Ryo H, Sakai H, Yoneda S, Noguchi Y. Bone metastasis of primary lung cancer. *Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.* 36:317-322, 1998
137. Sansur CA, Pouratian N, Dumont AS, Schiff D, Shaffrey CI, Shaffrey ME. Part II: spinal-cord neoplasms--primary tumours of the bony spine and adjacent soft tissues. *Lancet Oncol* 8:137-147, 2007
138. Schmidt BL. The neurobiology of cancer pain. *J Oral Maxillofac Surg* 73:S132-135, 2015
139. Schmidt BL. What pain tells us about cancer. *Pain* 156 Suppl 1:S32-34, 2015
140. Scott AC, McConnell S, Laird B, Colvin L, Fallon M. Quantitative Sensory Testing to assess the sensory characteristics of cancer-induced bone pain after radiotherapy and potential clinical biomarkers of response. *Eur J Pain* 16:123-133, 2012
141. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. *Pain* 155:2461-2470, 2014
142. Sestak I, Sapunar F, Cuzick J. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. *J Clin Oncol* 27:4961-4965, 2009
143. Sharma M, Simpson KH, Bennett MI, Gupta S: Practical Management of Complex Cancer Pain, Oxford University Press, Oxford, 2014.
144. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *Ca Cancer J Clin* 66:7-30, 2016
145. Silverman DT, Schiffman M, Everhart J, Goldstein A, Lillemoe KD, Swanson GM, Schwartz AG, Brown LM, Greenberg RS, Schoenberg JB, Potters LM, Hoover RN, Fraumeni JF, Jr. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. *Br J Cancer* 80:1830-1837, 1999
146. Slosky LM, Largent-Milnes TM, Vanderah TW. Use of animal models in understanding cancer-induced bone pain. *Cancer Growth Metastasis* 8:47-62, 2015
147. Stubblefield MD, McNeely ML, Alfano CM, Mayer DK. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy. *Cancer* 118:2250-2260, 2012
148. Taverner T. Neuropathic pain in people with cancer (part 1): incidence, manifestation, and assessment. *Int J Palliat Nurs* 20:442-447, 2014
149. Tersmette AC, Petersen GM, Offerhaus GJ, Falatko FC, Brune KA, Goggins M, Rozenblum E, Wilentz RE, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. *Clin Cancer Res* 7:738-744, 2001
150. Themistocleous AC. The pain in neuropathy study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy. *Pain* 157: 1132-45, 2016

151. Tofthagen C, Visovsky CM, Hopgood R. Chemotherapy-Induced Peripheral Neuropathy. *Clin J Oncol Nurs* 17:138-144, 2013
152. Toyama S, Shimoyama N, Ishida Y, Koyasu T, Szeto HH, Shimoyama M. Characterization of Acute and Chronic Neuropathies Induced by Oxaliplatin in Mice and Differential Effects of a Novel Mitochondria-targeted Antioxidant on the Neuropathies. *Anesthesiology* 120:459-473, 2014
153. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Kosek E, Lavand'homme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JW, Wang SJ. A classification of chronic pain for ICD-11. *Pain* 156:1003-1007, 2015
154. Trinkaus M, Simmons C, Myers J, Dranatisaris G, Clemons M. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. *Support Care Cancer* 18:197-203, 2010
155. Turk DC, Fillingim RB, Ohrbach R, Patel KV. Assessment of Psychosocial and Functional Impact of Chronic Pain. *J Pain* 17:T21-49, 2016
156. Vardeh D, Mannion RJ, Woolf CJ. Towards a mechanism based pain diagnosis. *J Pain* 17:T50-69, 2016
157. Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. *Pain* 157:560-568, 2016
158. Vichaya EG, Wang XS, Boyette-Davis JA, Mendoza TR, He Z, Thomas SK, Shah N, Williams LA, Cleeland CS, Dougherty PM. Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. *Cancer Chemother Pharmacol* 71:1531-1540, 2013
159. Wilson KG, Chochinov HM, Allard P, Chary S, Gagnon PR, Macmillan K, De Luca M, O'Shea F, Kuhl D, Fainsinger RL. Prevalence and correlates of pain in the Canadian National Palliative Care Survey. *Pain Res Manag* 14:365-370, 2009
160. Wong K, Zeng L, Zhang L, Bedard G, Wong E, Tsao M, Barnes E, Danjoux C, Sahgal A, Holden L, Lauzon N, Chow E. Minimal clinically important differences in the brief pain inventory in patients with bone metastases. *Support Care Cancer* 21:1893-1899, 2013
161. Yang Y, Zhang YG, Lin GA, Xie HQ, Pan HT, Huang BQ, Liu JD, Liu H, Zhang N, Li L, Chen JH. Spinal changes of a newly isolated neuropeptide endomorphin-2 concomitant with vincristine-induced allodynia. *PLoS One* 9:e89583, 2014
162. Zedan AH, Vilholm OJ. Chemotherapy-induced polyneuropathy: Major agents and assessment by questionnaires. *Basic Clin Pharmacol Toxicol* 115:193-200, 2014

**Legend****Figure 1. PRISMA diagram**

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) is an evidence-based minimum set of items for reporting systematic reviews

ACCEPTED MANUSCRIPT

Table 1. Dimension 1: Core Diagnostic Criteria for CIBP

1. History of primary or metastatic bone cancer diagnosed by imaging and physical examination
2. Presence of continuous, background pain (usually described as annoying, dull, gnawing, aching, and/or nagging) in one or more locations generally consistent with known distribution of bone lesions<sup>40, 41, 43, 49, 50, 61, 92, 133</sup>
3. Presence of evoked or spontaneous pain (often described as electric or shock-like) in one or more locations generally consistent with known distribution of bone lesions, associated with weight bearing or movement or can occur spontaneously<sup>40, 41, 43, 48-50, 61, 85, 92, 133</sup>
4. Clinical examination over the site of pain reveals:
  - Hyperalgesia to blunt, non-noxious pressure or pin-prick stimuli or
  - Hypoesthesia to non-noxious thermal stimuli or
  - Hypoesthesia to light touch stimuli<sup>140</sup>

Table 2. Dimension 1: Core Diagnostic Criteria for CIPN

1. Onset of pain following exposure to a chemotherapeutic agent known to be neurotoxic
2. Presence of painful symptoms in a symmetrical stocking and glove distribution beginning in lower extremities which may progress to the upper extremities, although finding in the feet and not in the hands are common
3. Painful symptoms are accompanied by non-painful symptoms (e.g., “pins and needles” or numbness) in a similar distribution.
4. Clinical examination reveals sensory loss to one or more sensory modalities and/or evoked pain in a stocking and glove distribution, as reflected in at least one of the following:
  - Hypoesthesia – bilateral increase in detection thresholds to tactile, vibration, or non-noxious warm or cool stimuli or
  - Hypoalgesia – bilateral increase in pain detection thresholds to blunt pressure or pinprick stimuli, or
  - Hyperalgesia – bilateral decrease in pain detection threshold to noxious heat or cold stimuli
5. Magnitude of the sensory abnormalities is disproportionately greater than the magnitude of any motor abnormalities in the affected region (except in the case of neuropathy after vinca alkaloids)
6. No other condition (e.g., polyneuropathy of other origin) could plausibly account for painful symptoms

Table 3. Dimension 1: Core Diagnostic Criteria for PCP

1. History of pancreatic cancer diagnosed by imaging, physical examination, and in some cases biopsy and laboratory analysis of blood or tissues for tumor markers
2. Presence of pain in upper abdominal region (typically referred to the epigastric region or upper abdominal quadrants) spreading posteriorly and/or radiating to the back
3. On clinical examination, the patient displays tenderness on upper abdominal palpation
4. No other condition (e.g., constipation) could plausibly account for persisting pain in the upper abdomen






Figure 1. PRISMA diagram

**AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions*****Highlights***

- No comprehensive, universally accepted cancer pain classification system currently exists.
- An evidence-based taxonomy would enhance cancer pain research efforts by providing consistent diagnostic criteria, ensuring comparability across clinical trials.
- As part of a collaborative effort between the Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks (ACTTION) and the American Pain Society (APS), the ACTTION-APS Pain Taxonomy (AAPT) initiative worked to develop the characteristics of an optimal diagnostic system for cancer pain.
- Diagnostic criteria were developed for three chronic pain syndromes associated with cancer (i.e., bone pain and pancreatic cancer pain as models of pain related to a tumor) or its treatment (i.e., chemotherapy-induced peripheral neuropathy). Future efforts will subject these diagnostic categories and criteria to systematic empirical evaluation of their feasibility, reliability and validity and extension to other cancer-related pain syndromes.